19th Annual Non-Dilutive Funding Summit
The 19th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, SEED, NINDS, NHLBI, NIMHD, NCI and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2023 FreeMind Elite honorees from AmplifiDx, Sapience Therapeutics, Marker Therapeutics, and Vincere Biosciences took to the stage to present about their compies research and pipelines.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 20th Non-Dilutive Funding Summit will be January 8, 2025.
“NIH Supports Product Development”
Small business Education and Entrepreneurial Development (SEED)
SEED was created to accelerate the conversion of scientific discoveries into healthcare solutions, creating a world where scientists are ebcouraged to improve the lives of patients and their families.
SEED’s core objectives are:
- Identify and scale approaches that enable investigators to convert scientific discoveries into impactful healthcare solutions
- Coordinate early-stage product development activities across the NIH
- Inspire and support a diverse entrepreneurial workforce
- Demonstrate NIH’s role in improving patient care and driving economic growth
Developing products across the biomedical spectrum requires NIH to collaborate with universities and research institutions, small businesses, trade associations and societies, angel investors, venture capitalists, and strategic partners. And SEEd is able to help develop these relationships and create opportunities for NIH funded innovators and propel them to further their product development efforts.
Matthew McMahon
Director, NIH SEED (Small business Education and Entrepreneurial Development)
Matt leads the SEED Office (Small business Education and Entrepreneurial Development) in helping to transform cutting-edge technologies into products that improve health and save lives. The SEED team educates and assists NIH-funded innovators as they transition from discovery science to product development. SEED helps academic innovators validate the potential health impacts of their discoveries through a national network of proof-of-concept centers and provides a host of professional advisory services to small business innovators funded by NIH’s $1.3 billion/year SBIR and STTR programs. Matt has a diverse background in academia, small business, congressional policy, and NIH program management. He previously served as the first director of the National Heart, Lung, and Blood Institute’s Office of Translational Alliances and Coordination, and he created and led the National Eye Institute’s Office of Translational Research. His previous experience also includes service as the principal scientist for the bionic eye company Second Sight Medical Products and as a staff member on both the United States Senate and House of Representatives committees responsible for science, technology, and innovation policy.
